INAB
In8bio Inc
NASDAQ: INAB · HEALTHCARE · BIOTECHNOLOGY
$1.47
-2.65% today
Updated 2026-04-30
Market cap
$15.36M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-4.44
Dividend yield
—
52W range
$1 – $6
Volume
0.1M
In8bio Inc (INAB) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
2 of 8
Last 8 quarters
Avg EPS surprise
-148.7%
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
-462.5%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+1.5%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
+7.9%
2026-03-13
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-13 | $-0.45 | +5.3% | $1.91 | $2.06 | +7.9% |
| 2025-11-06 | $-0.85 | -1600.0% | $1.63 | $1.55 | -4.9% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.48 | $-0.45 | +5.3% | — | — |
| 2025-09-30 | $-0.05 | $-0.85 | -1600.0% | — | — |
| 2025-06-30 | $-0.06 | $-1.24 | -1966.7% | — | — |
| 2025-03-31 | $-0.07 | $-2.10 | -2796.6% | — | — |
| 2024-12-31 | $-0.07 | $-0.08 | -14.3% | $2.53M | -32.6% |
| 2024-09-30 | $-0.17 | $-0.15 | +11.8% | — | — |
| 2024-06-30 | $-0.17 | $-0.19 | -11.8% | — | — |
| 2024-03-31 | $-0.18 | $-0.20 | -11.1% | — | — |
| 2023-12-31 | $-0.15 | $-0.21 | -40.0% | $3.75M | — |
| 2023-09-30 | $-0.24 | $-0.23 | +4.2% | — | — |
| 2023-06-30 | $-0.27 | $-0.27 | +0.0% | — | — |
| 2023-03-31 | $-0.32 | $-0.30 | +6.3% | $330000.00 | — |
Frequently asked questions
Has In8bio Inc beaten earnings estimates?
In8bio Inc has beaten Wall Street EPS estimates in 2 of its last 8 quarterly reports, with an average EPS surprise of -148.7% over the last 4 quarters.
How does INAB stock react to earnings?
INAB stock has moved an average of +1.5% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.